OSMIND

Osmind is the premier platform for psychedelic-assisted psychotherapy practices. The all-in-one platform includes purpose-built charting for ketamine, SPRAVATO, psychotherapy and more; as well as patient tools for the therapeutic alliance that include 40+ validated rating scales and a patient app for journaling and secure messaging too. Visit Osmind using our link below:

Episode Description:

In this episode, we interview Max Wolff. Max Wolff is a psychologist and psychotherapist, and serves as the Head of Psychotherapy Training and Research at the MIND Foundation. We discuss the EPIsoDE psilocybin trial that Max is involved with in Germany, perspectives on how to properly conduct psychedelic therapy, differences between Germany and the United States when it comes to therapy and psychedelics, and more.

Show Notes:

-4:00 EPIsoDE Study (Clinical Trial):

https://episode-study.de/

https://mind-foundation.org/research/episode-study/

-41:00 Psychotherapy in Germany:

https://www.ncbi.nlm.nih.gov/books/NBK279513/#:~:text=Statutory%20health%20insurers%20cover%20up,part%20of%20group%20therapy%20sessions.

-48:30 Insight Conference in Berlin:

https://insight-conference.eu/

-55:30 MIND Foundation:

https://mind-foundation.org/

Learning to Let Go journal article:

https://www.frontiersin.org/articles/10.3389/fpsyt.2020.00005/full

Episode 34: The indefatigable Max Wolff